Of the 20 million new cancer cases diagnosed each year worldwide, 85% are solid tumours. Unfortunately, solid tumours are resistant to cell therapies. CytoSeek Ltd, a spin-out from the University of Bristol, has developed artificial membrane-binding protein (AMBP) technology for the next generation of cell therapies that will target solid tumours.
In early 2021, the discovery-stage biotech company successfully raised a £3.57 million seed round. This will allow CytoSeek to expand its research programme and the operational team to address this unmet need.
Dr Ben Carter is Co-Founder and Chief Operating Officer at CytoSeek. Ben is responsible for running operations, project management, patenting matters, liaising with collaborators, and dealing with contracts and suppliers. He joined the Scale Up Accelerator programme in 2021 and says: “I look forward to networking with like-minded businesspeople, which will be useful in uncovering unknown-unknowns. In addition, there will be people with investment experience and that will allow me to further develop my negotiation skills.”
CytoSeek is developing a broad pipeline of therapeutics based on its patented AMBP platform. Its mission for cell therapies to treat cancerous solid tumours is well underway. When it closes its forthcoming Series A financing round, the company will proceed to clinical trials and scale up its manufacturing capabilities.
Associated Programme
